Among its findings, the report notes:
1. The global market for gastrointestinal drugs reached $35.7 billion in 2015.
2. The market is expected to reach $48.4 billion by 2022, growing at a CAGR of 4.45 percent.
3. At present, AbbVie is leading the market; however, Takeda Pharmaceutical is expected to be the leading market player by the end of 2022.
4. Other key market players include Johnson & Johnson, Allergan and AstraZeneca.
5. GBI Research says that this increase in market value is, in part, due to a growing interest in biologic products.
More articles on gastroenterology and endoscopy:
Cologuard included in 2017 HEDIS quality measures for CRC screening: 4 notes
Allergan buys rights to AstraZeneca’s IBD treatment drug for $250M: 3 notes
Global market for endoscopic devices to grow at 7.06% CAGR until 2020: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
